Peringatan Keamanan

Sevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.

Sevelamer

DB00658

small molecule approved

Deskripsi

Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.

Struktur Molekul 2D

Berat 149.619
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease. Sevelamer may bind to dietary phosphates and prevent its gastrointestinal absorption when sevelamer is administered in combination with food.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with food.

Interaksi Obat

372 Data
Cyclosporine The serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.
Moxifloxacin Sevelamer can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Grepafloxacin Sevelamer can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Enoxacin Sevelamer can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pefloxacin Sevelamer can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ciprofloxacin Sevelamer can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trovafloxacin Sevelamer can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nalidixic acid Sevelamer can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rosoxacin Sevelamer can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cinoxacin Sevelamer can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lomefloxacin Sevelamer can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gatifloxacin Sevelamer can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norfloxacin Sevelamer can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levofloxacin Sevelamer can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gemifloxacin Sevelamer can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ofloxacin Sevelamer can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sparfloxacin Sevelamer can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Temafloxacin Sevelamer can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fleroxacin Sevelamer can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Technetium Tc-99m ciprofloxacin Sevelamer can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Garenoxacin Sevelamer can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nemonoxacin Sevelamer can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Flumequine Sevelamer can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Enrofloxacin Sevelamer can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Orbifloxacin Sevelamer can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sarafloxacin Sevelamer can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Difloxacin Sevelamer can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pazufloxacin Sevelamer can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prulifloxacin Sevelamer can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Delafloxacin Sevelamer can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sitafloxacin Sevelamer can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxolinic acid Sevelamer can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rufloxacin Sevelamer can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pipemidic acid Sevelamer can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Amiodarone The excretion of Amiodarone can be increased when combined with Sevelamer.
Pravastatin Sevelamer can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lovastatin Sevelamer can cause a decrease in the absorption of Lovastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cerivastatin Sevelamer can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Simvastatin Sevelamer can cause a decrease in the absorption of Simvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Atorvastatin Sevelamer can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluvastatin Sevelamer can cause a decrease in the absorption of Fluvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rosuvastatin Sevelamer can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mevastatin Sevelamer can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pitavastatin Sevelamer can cause a decrease in the absorption of Pitavastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ursodeoxycholic acid Sevelamer can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Glycochenodeoxycholic Acid Sevelamer can cause a decrease in the absorption of Glycochenodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic Acid Sevelamer can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Glycocholic acid Sevelamer can cause a decrease in the absorption of Glycocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Deoxycholic acid Sevelamer can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Taurocholic acid Sevelamer can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chenodeoxycholic acid Sevelamer can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Taurochenodeoxycholic acid Sevelamer can cause a decrease in the absorption of Taurochenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tauroursodeoxycholic acid Sevelamer can cause a decrease in the absorption of Tauroursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bamet-UD2 Sevelamer can cause a decrease in the absorption of Bamet-UD2 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dehydrocholic acid Sevelamer can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hyodeoxycholic Acid Sevelamer can cause a decrease in the absorption of Hyodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Deferasirox Sevelamer can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ezetimibe Sevelamer can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy.
Leflunomide Sevelamer may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.
Teriflunomide Sevelamer may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy.
Lomitapide Sevelamer can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methotrexate Sevelamer may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.
Niacin Sevelamer can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Propranolol Sevelamer can cause a decrease in the absorption of Propranolol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Raloxifene Sevelamer can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.
Vancomycin The therapeutic efficacy of Vancomycin can be decreased when used in combination with Sevelamer.
Levothyroxine The serum concentration of Levothyroxine can be decreased when it is combined with Sevelamer.
Tacrolimus The serum concentration of Tacrolimus can be decreased when it is combined with Sevelamer.
Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Sevelamer.
Lithium citrate The absorption of Lithium citrate can be decreased when combined with Sevelamer.
Lithium carbonate The absorption of Lithium carbonate can be decreased when combined with Sevelamer.
Lithium hydroxide The absorption of Lithium hydroxide can be decreased when combined with Sevelamer.
Digoxin Sevelamer can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetyldigitoxin Sevelamer can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Deslanoside Sevelamer can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ouabain Sevelamer can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.
Digitoxin Sevelamer can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oleandrin Sevelamer can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cymarin Sevelamer can cause a decrease in the absorption of Cymarin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Proscillaridin Sevelamer can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metildigoxin Sevelamer can cause a decrease in the absorption of Metildigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lanatoside C Sevelamer can cause a decrease in the absorption of Lanatoside C resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gitoformate Sevelamer can cause a decrease in the absorption of Gitoformate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetyldigoxin Sevelamer can cause a decrease in the absorption of Acetyldigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Peruvoside Sevelamer can cause a decrease in the absorption of Peruvoside resulting in a reduced serum concentration and potentially a decrease in efficacy.
Desogestrel Sevelamer can cause a decrease in the absorption of Desogestrel resulting in a reduced serum concentration and potentially a decrease in efficacy.
Megestrol acetate Sevelamer can cause a decrease in the absorption of Megestrol acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levonorgestrel Sevelamer can cause a decrease in the absorption of Levonorgestrel resulting in a reduced serum concentration and potentially a decrease in efficacy.
Medroxyprogesterone acetate Sevelamer can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norethisterone Sevelamer can cause a decrease in the absorption of Norethisterone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Estradiol Sevelamer can cause a decrease in the absorption of Estradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ethynodiol diacetate Sevelamer can cause a decrease in the absorption of Ethynodiol diacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mifepristone Sevelamer can cause a decrease in the absorption of Mifepristone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norgestimate Sevelamer can cause a decrease in the absorption of Norgestimate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ethinylestradiol Sevelamer can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Drospirenone Sevelamer can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cyproterone acetate Sevelamer can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gestodene Sevelamer can cause a decrease in the absorption of Gestodene resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dienogest Sevelamer can cause a decrease in the absorption of Dienogest resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norethynodrel Sevelamer can cause a decrease in the absorption of Norethynodrel resulting in a reduced serum concentration and potentially a decrease in efficacy.

Target Protein

Phosphate

Referensi & Sumber

Synthesis reference: Deepak Anant Hedge, Varsha Shashank Choudhary, Venkatasubramanian Radhakrjshnan Tarur, Dhananjay Govind Sathe, Harish Kashinath Mondkar, Samadhan Daulat Patil, Sasikumar Mohan Thoovara, Yogesh Sharad Bhide, "Process for the Preparation of Sevelamer Hydrochloride and Formulation Thereof." U.S. Patent US20090280178, issued November 12, 2009.

Contoh Produk & Brand

Produk: 129 • International brands: 1
Produk
  • Accel-sevelamer
    Tablet • 800 mg • Oral • Canada • Generic • Approved
  • Intelli-sevelamer
    Tablet • 800 mg • Oral • Canada • Approved
  • Renagel
    Tablet • 800 mg/1 • Oral • US • Approved
  • Renagel
    Tablet • 800 mg/1 • Oral • US • Approved
  • Renagel
    Tablet • 800 mg/1 • Oral • US • Approved
  • Renagel
    Tablet • 800 mg/1 • Oral • US • Approved
  • Renagel
    Tablet • 800 mg/1 • Oral • US • Approved
  • Renagel
    Tablet • 400 mg/1 • Oral • US • Approved
Menampilkan 8 dari 129 produk.
International Brands
  • Phosblock — Kyowa Hakko Kirin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul